Lilly(US:LLY) Zhi Tong Cai Jing·2025-06-20 12:39Core Viewpoint - Eli Lilly (LLY.US) plans to appeal the UK health authorities' decision to reject the recommendation of its new Alzheimer's drug, Kisunla, for inclusion in the public healthcare system due to cost considerations [1][2] Group 1: Regulatory Decisions - The National Institute for Health and Care Excellence (NICE) released a final draft stating that both Kisunla and Biogen's Leqembi should not be used within the National Health Service (NHS) [1] - NICE's independent expert committee concluded that the clinical benefits of these two targeted amyloid beta antibodies do not justify the additional costs to the NHS [1][2] Group 2: Company Response - Eli Lilly argues that the NICE recommendation is unfair, citing data submitted by the company, clinical experts, and patient advocacy groups [1] - The company intends to appeal the decision made by NICE regarding the inclusion of Kisunla in the NHS [1] Group 3: Approval Status - Both Leqembi and Kisunla were approved by the UK Medicines and Healthcare products Regulatory Agency (MHRA) for the treatment of mild Alzheimer's disease in adult patients in 2024 [1]